ES2264563T3 - Particulas semejantes al virus del papiloma, proteinas de fusion y procedimiento para su preparacion. - Google Patents
Particulas semejantes al virus del papiloma, proteinas de fusion y procedimiento para su preparacion.Info
- Publication number
- ES2264563T3 ES2264563T3 ES95934663T ES95934663T ES2264563T3 ES 2264563 T3 ES2264563 T3 ES 2264563T3 ES 95934663 T ES95934663 T ES 95934663T ES 95934663 T ES95934663 T ES 95934663T ES 2264563 T3 ES2264563 T3 ES 2264563T3
- Authority
- ES
- Spain
- Prior art keywords
- proteins
- protein
- virus
- particles
- papillomavirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 23
- 239000002245 particle Substances 0.000 title claims description 72
- 108020001507 fusion proteins Proteins 0.000 title claims description 50
- 102000037865 fusion proteins Human genes 0.000 title claims description 50
- 238000000034 method Methods 0.000 title claims description 23
- 238000002360 preparation method Methods 0.000 title claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 166
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 165
- 238000012217 deletion Methods 0.000 claims abstract description 26
- 230000037430 deletion Effects 0.000 claims abstract description 26
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- 238000000338 in vitro Methods 0.000 claims abstract description 4
- 235000018102 proteins Nutrition 0.000 claims description 162
- 241001631646 Papillomaviridae Species 0.000 claims description 41
- 239000012634 fragment Substances 0.000 claims description 20
- 238000002255 vaccination Methods 0.000 claims description 18
- 229960005486 vaccine Drugs 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 241000701822 Bovine papillomavirus Species 0.000 claims description 13
- 210000004899 c-terminal region Anatomy 0.000 claims description 12
- 230000000069 prophylactic effect Effects 0.000 claims description 12
- 241000588724 Escherichia coli Species 0.000 claims description 11
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 10
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- 241000701447 unidentified baculovirus Species 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 7
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 7
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 7
- 210000000805 cytoplasm Anatomy 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 241000388186 Deltapapillomavirus 4 Species 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 101000808044 Equine herpesvirus 1 (strain Kentucky A) Gene 3 protein Proteins 0.000 claims description 5
- 101710172711 Structural protein Proteins 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 208000003154 papilloma Diseases 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 229920002113 octoxynol Polymers 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 238000004925 denaturation Methods 0.000 claims description 3
- 230000036425 denaturation Effects 0.000 claims description 3
- 235000014304 histidine Nutrition 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 claims description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 2
- 238000004153 renaturation Methods 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 235000011148 calcium chloride Nutrition 0.000 claims 1
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 108010087302 Viral Structural Proteins Proteins 0.000 abstract description 3
- 241000701806 Human papillomavirus Species 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 14
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 9
- 239000002253 acid Substances 0.000 description 6
- 208000015698 cervical squamous intraepithelial neoplasia Diseases 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 5
- 208000019065 cervical carcinoma Diseases 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 206010059313 Anogenital warts Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 208000000907 Condylomata Acuminata Diseases 0.000 description 2
- 206010061978 Genital lesion Diseases 0.000 description 2
- 241000701828 Human papillomavirus type 11 Species 0.000 description 2
- 208000009608 Papillomavirus Infections Diseases 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 2
- 201000004201 anogenital venereal wart Diseases 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 150000002411 histidines Chemical class 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701585 Human papillomavirus type 15 Species 0.000 description 1
- 241000701646 Kappapapillomavirus 2 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010057576 Papillomavirus E7 Proteins Proteins 0.000 description 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940037642 autologous vaccine Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4435907 | 1994-10-07 | ||
| DE19944435907 DE4435907C2 (de) | 1994-10-07 | 1994-10-07 | Papillomavirusähnliche Partikel und deren Anwendung |
| DE1995126752 DE19526752C2 (de) | 1995-07-21 | 1995-07-21 | Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln |
| DE19526752 | 1995-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2264563T3 true ES2264563T3 (es) | 2007-01-01 |
Family
ID=25940851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES95934663T Expired - Lifetime ES2264563T3 (es) | 1994-10-07 | 1995-10-09 | Particulas semejantes al virus del papiloma, proteinas de fusion y procedimiento para su preparacion. |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US6066324A (enExample) |
| EP (2) | EP1728800A1 (enExample) |
| JP (6) | JPH11504801A (enExample) |
| AT (1) | ATE325875T1 (enExample) |
| AU (2) | AU4270196A (enExample) |
| CA (1) | CA2202090C (enExample) |
| DE (3) | DE122007000093I1 (enExample) |
| DK (1) | DK0809700T3 (enExample) |
| ES (1) | ES2264563T3 (enExample) |
| LU (2) | LU91401I2 (enExample) |
| NL (2) | NL300323I2 (enExample) |
| PT (1) | PT809700E (enExample) |
| WO (1) | WO1996011272A2 (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164350A1 (en) | 1992-09-03 | 2002-11-07 | Lowy Douglas R. | Chimeric papillomavirus-like particles |
| US8062642B1 (en) | 1993-03-09 | 2011-11-22 | University Of Rochester | Production of papillomavirus capsid protein and virus-like particles |
| AU4270196A (en) * | 1994-10-07 | 1996-05-02 | Lutz Gissmann | Papilloma virus-like particles, fusion proteins and process for producing the same |
| JP2000515741A (ja) | 1996-07-17 | 2000-11-28 | アメリカ合衆国 | 感染性パピローマウイルス偽ウイルス粒子 |
| DE19631357A1 (de) * | 1996-08-02 | 1998-02-05 | Deutsches Krebsforsch | Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen |
| GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
| WO1998028003A1 (en) * | 1996-12-20 | 1998-07-02 | Merck & Co., Inc. | Formulations of recombinant papillomavirus vaccines |
| WO1999001557A1 (en) * | 1997-07-03 | 1999-01-14 | University Of Colorado, University Technology Corporation | Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy |
| US7351533B2 (en) * | 1997-09-05 | 2008-04-01 | Medimmune, Inc. | In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents |
| US6228368B1 (en) * | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
| AU2003200653B2 (en) * | 1997-10-06 | 2007-01-18 | Loyola University Of Chicago | Papilloma virus capsomere vaccine formulations and methods of use |
| US7494658B2 (en) | 1998-02-20 | 2009-02-24 | Medigene Ag | Papilloma virus truncated L1 protein and fusion protein constructs |
| CA2229955C (en) | 1998-02-20 | 2003-12-09 | Medigene Gmbh | Papilloma virus capsomere vaccine formulations and methods of use |
| US7182947B2 (en) * | 1998-02-20 | 2007-02-27 | Medigene Ag | Papillomavirus truncated L1 protein and fusion protein constructs |
| US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
| US6926897B1 (en) | 1998-03-24 | 2005-08-09 | Medigene Aktiengesellschaft | Medicament for the avoidance or treatment of papillomavirus-specific tumour |
| DE19812940A1 (de) * | 1998-03-24 | 1999-10-07 | Medigene Ag | Formulierung mit Papillomavirus-spezifischem Protein, seine Herstellung und Verwendung |
| GB9806666D0 (en) * | 1998-03-27 | 1998-05-27 | Stanley Margaret | Antigen preparation and use |
| CA2339324C (en) * | 1998-08-14 | 2011-05-31 | Robert S. Lowe | Protein delivery system using human papillomavirus virus-like particles |
| US6991795B1 (en) * | 1998-08-14 | 2006-01-31 | Merck & Co., Inc. | Protein delivery system using human papillomavirus virus-like particles |
| AU750587B2 (en) | 1998-10-16 | 2002-07-25 | Smithkline Beecham Biologicals (Sa) | Adjuvant systems and vaccines |
| SE514982C2 (sv) * | 1999-09-30 | 2001-05-28 | Active Biotech Ab | Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning |
| DE19925199A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
| DE19925235A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
| US20040146531A1 (en) * | 1999-09-30 | 2004-07-29 | Active Biotech Ab | Virus-like particles devoid of HPV 16 type-specific antibody epitopes as carriers of peptides for introduction into cells |
| US6908613B2 (en) * | 2000-06-21 | 2005-06-21 | Medimmune, Inc. | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor |
| ATE418997T1 (de) * | 2000-07-06 | 2009-01-15 | Univ Georgetown | Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen |
| GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
| DE10137102A1 (de) * | 2001-07-30 | 2003-02-27 | Deutsches Krebsforsch | Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung |
| GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| US9045727B2 (en) * | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
| DK1506222T3 (da) * | 2002-05-17 | 2009-07-06 | Univ Cape Town | Kimæriske, humane papillomavirus16 L1-proteiner omfattende et L2-peptid, viruslignende partikler fremstillet deraf samt en fremgangsmåde til at fremstille partiklerne |
| US20060088909A1 (en) * | 2002-05-17 | 2006-04-27 | Compans Richard W | Virus-like particles, methods of preparation, and immunogenic compositions |
| US7858098B2 (en) * | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
| US20080160040A1 (en) * | 2004-04-15 | 2008-07-03 | Ghim Shin-Je | Plant-produced compositions for treating papillomavirus infection and related methods |
| US7972776B2 (en) * | 2005-11-15 | 2011-07-05 | Oncohealth Corporation | Protein chips for HPV detection |
| US7732166B2 (en) * | 2005-11-15 | 2010-06-08 | Oncohealth Corporation | Detection method for human pappilomavirus (HPV) and its application in cervical cancer |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| US8778351B2 (en) | 2006-08-30 | 2014-07-15 | University Of Rochester | Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors |
| CN101148661B (zh) * | 2006-09-18 | 2013-01-02 | 中国医学科学院基础医学研究所 | 人乳头瘤病毒16型外壳蛋白病毒样颗粒及其制备方法和用途 |
| KR101378872B1 (ko) | 2006-09-26 | 2014-04-11 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | 합성 애주번트를 함유하는 백신 조성물 |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US8968995B2 (en) * | 2008-11-12 | 2015-03-03 | Oncohealth Corp. | Detection, screening, and diagnosis of HPV-associated cancers |
| US8859218B2 (en) | 2008-06-13 | 2014-10-14 | Oncohealth Corp. | In situ detection of early stages and late stages HPV infection |
| WO2008115631A2 (en) * | 2007-02-08 | 2008-09-25 | University Of Louisville Research Foundation, Inc. | Plant-produced compositions for treating papillomavirus infection and related methods |
| CA2679410C (en) | 2007-03-02 | 2017-01-17 | Glaxosmithkline Biologicals S.A. | Novel method and compositions |
| US9428555B2 (en) | 2007-04-29 | 2016-08-30 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Truncated L1 protein of Human Papillomavirus type 16 |
| DK2147926T3 (en) | 2007-04-29 | 2016-11-28 | Beijing Wantai Biological Pharmacy Entpr Co Ltd | Truncated human papillomavirus type 18 L1 protein |
| US8748127B2 (en) * | 2007-05-29 | 2014-06-10 | Xiamen University | Truncated L1 protein of human papillomavirus type 6 |
| US20100260792A1 (en) * | 2007-10-22 | 2010-10-14 | University Of Rochester | Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres |
| EP2479187A1 (en) * | 2007-11-23 | 2012-07-25 | Shanghai Zerun Biotechnology Co., Ltd. | Genes encoding major capsid protein L1 of human papilloma viruses |
| GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
| GB0820822D0 (en) | 2008-11-13 | 2008-12-24 | Inst Catala D Oncologia | Novel product and processes |
| CN102449479B (zh) | 2009-05-07 | 2015-11-25 | 安科健康公司 | 鉴别高度或≥cin2用于人乳头瘤病毒(hpv)与hpv相关癌症的早期及晚期检测、筛检和诊断 |
| SI2437753T1 (sl) | 2009-06-05 | 2016-12-30 | Infectious Disease Research Institute | Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo |
| JP5819851B2 (ja) | 2010-01-08 | 2015-11-24 | オンコヘルス コーポレーション | Ｈｐｖ関連の癌の治療及びスクリーニングのための細胞に基づいた高処理能力ｈｐｖ免疫アッセイ |
| AU2012243039B2 (en) | 2011-04-08 | 2017-07-13 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| WO2012174220A1 (en) * | 2011-06-14 | 2012-12-20 | Globeimmune, Inc. | Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection |
| KR102049988B1 (ko) | 2011-06-24 | 2019-11-28 | 머크 샤프 앤드 돔 코포레이션 | 알루미늄 아주반트를 포함하는 hpv 백신 제제 및 그의 제조 방법 |
| AU2012304993B2 (en) | 2011-09-08 | 2017-09-14 | Uniqure Ip B.V. | Removal of contaminating viruses from AAV preparations |
| CN110339160A (zh) | 2012-02-07 | 2019-10-18 | 传染性疾病研究院 | 包含tlr4激动剂的改进佐剂制剂及其使用方法 |
| WO2013139744A1 (en) | 2012-03-18 | 2013-09-26 | Glaxosmithkline Biologicals S.A. | Method of vaccination against human papillomavirus |
| PT2850431T (pt) | 2012-05-16 | 2018-07-23 | Immune Design Corp | Vacinas para hsv-2 |
| EP3711768A1 (en) | 2013-04-18 | 2020-09-23 | Immune Design Corp. | Gla monotherapy for use in cancer treatment |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| CN104231060B (zh) * | 2013-06-05 | 2018-05-15 | 厦门大学 | 人乳头瘤病毒l1l2衣壳蛋白相互作用位点及其应用 |
| IL310015B2 (en) | 2013-12-31 | 2026-02-01 | Access To Advanced Health Inst | Single vial formulation |
| EP4112638A1 (en) | 2016-05-16 | 2023-01-04 | Access to Advanced Health Institute | Formulation containing tlr agonist and methods of use |
| IL263030B2 (en) | 2016-05-16 | 2024-11-01 | Access To Advanced Health Inst | Pegylated liposomes and methods of use |
| KR102748354B1 (ko) | 2016-06-01 | 2024-12-31 | 액세스 투 어드밴스드 헬스 인스티튜트 | 사이징제를 함유하는 나노명반 입자 |
| KR102673794B1 (ko) | 2017-06-15 | 2024-06-11 | 액세스 투 어드밴스드 헬스 인스티튜트 | 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도 |
| CN111315406A (zh) | 2017-09-08 | 2020-06-19 | 传染病研究所 | 包括皂苷的脂质体调配物及其使用方法 |
| US11261216B2 (en) * | 2018-12-28 | 2022-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered hepatitis B core polypeptide |
| BR112021023726A2 (pt) | 2019-05-25 | 2022-02-15 | Infectious Disease Res Inst | Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante |
| WO2021013063A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人乳头瘤病毒16型l1蛋白 |
| KR102767403B1 (ko) | 2019-07-19 | 2025-02-14 | 사이노셀테크 엘티디. | 키메라 유두종바이러스 l1 단백질 |
| CA3147849A1 (en) | 2019-07-19 | 2021-01-28 | Sinocelltech Ltd. | Polyvalent immunogenicity composition for human papillomavirus |
| CN114127097B (zh) * | 2019-07-19 | 2024-09-17 | 神州细胞工程有限公司 | 嵌合的人乳头瘤病毒56型l1蛋白 |
| CN114127099B (zh) * | 2019-07-19 | 2024-04-19 | 神州细胞工程有限公司 | 嵌合的人乳头瘤病毒6型l1蛋白 |
| BR112022015313A2 (pt) | 2020-02-14 | 2022-09-27 | Merck Sharp & Dohme Llc | Vacina de hpv |
| CA3174411A1 (en) | 2020-09-04 | 2022-03-10 | Ryan M. Kramer | Co-lyophilized rna and nanostructured lipid carrier |
| CN114539363B (zh) * | 2020-11-26 | 2023-12-01 | 中国医学科学院基础医学研究所 | 一种c端改造的人乳头瘤病毒11型l1蛋白及其用途 |
| CN114539365B (zh) * | 2020-11-26 | 2023-12-01 | 中国医学科学院基础医学研究所 | 一种改造的人乳头瘤病毒52型l1蛋白及其用途 |
| US20240131140A1 (en) | 2021-02-11 | 2024-04-25 | Glaxosmithkline Biologicals Sa | Hpv vaccine manufacture |
| WO2022268811A1 (en) | 2021-06-21 | 2022-12-29 | Uniqure Biopharma B.V. | Improved lysis procedures |
| AR126708A1 (es) | 2021-08-06 | 2023-11-08 | Merck Sharp & Dohme Llc | Vacuna para el vph |
| CA3229064A1 (en) | 2021-08-19 | 2023-02-23 | Andrew Bett | Thermostable lipid nanoparticle and methods of use thereof |
| EP4583841A1 (en) | 2022-09-09 | 2025-07-16 | Access to Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
| TW202513091A (zh) | 2023-06-09 | 2025-04-01 | 美商默沙東有限責任公司 | 用於人類乳突病毒疫苗之奈米乳液佐劑組合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9113809D0 (en) * | 1991-06-26 | 1991-08-14 | Cancer Res Campaign Tech | Papillomavirus l2 protein |
| DE69233639T2 (de) * | 1991-07-19 | 2007-05-31 | Csl Ltd., Parkville | Polynukleotidabschnitt des HPV16-Genoms |
| GB9207701D0 (en) | 1992-04-08 | 1992-05-27 | Cancer Res Campaign Tech | Papillomavirus e7 protein |
| EP0565794A1 (en) * | 1992-04-14 | 1993-10-20 | British Biotech Pharmaceuticals Limited | Induction of CTL responses |
| PT647140E (pt) | 1992-06-25 | 2007-12-27 | Univ Georgetown | Vacinas de papilomavírus |
| US5618536A (en) * | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
| US5437951A (en) * | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
| ATE296111T1 (de) * | 1993-03-09 | 2005-06-15 | Univ Rochester | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen |
| AU4270196A (en) * | 1994-10-07 | 1996-05-02 | Lutz Gissmann | Papilloma virus-like particles, fusion proteins and process for producing the same |
| WO1996026277A1 (en) * | 1995-02-24 | 1996-08-29 | Cantab Pharmaceuticals Research Limited | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
| US5874089A (en) * | 1995-10-02 | 1999-02-23 | Georgetown University School Of Medicine | Protecting against canine oral papillomavirus (copy) |
| US6228368B1 (en) * | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
-
1995
- 1995-10-09 AU AU42701/96A patent/AU4270196A/en not_active Abandoned
- 1995-10-09 JP JP8512335A patent/JPH11504801A/ja not_active Withdrawn
- 1995-10-09 EP EP06009351A patent/EP1728800A1/de not_active Withdrawn
- 1995-10-09 EP EP95934663A patent/EP0809700B1/de not_active Expired - Lifetime
- 1995-10-09 PT PT95934663T patent/PT809700E/pt unknown
- 1995-10-09 DE DE122007000093C patent/DE122007000093I1/de active Pending
- 1995-10-09 CA CA2202090A patent/CA2202090C/en not_active Expired - Lifetime
- 1995-10-09 DE DE122007000092C patent/DE122007000092I1/de active Pending
- 1995-10-09 US US08/817,335 patent/US6066324A/en not_active Expired - Lifetime
- 1995-10-09 ES ES95934663T patent/ES2264563T3/es not_active Expired - Lifetime
- 1995-10-09 DK DK95934663T patent/DK0809700T3/da active
- 1995-10-09 WO PCT/EP1995/003974 patent/WO1996011272A2/de not_active Ceased
- 1995-10-09 DE DE59511047T patent/DE59511047D1/de not_active Expired - Lifetime
- 1995-10-09 AT AT95934663T patent/ATE325875T1/de active
-
1999
- 1999-09-16 US US09/397,680 patent/US6361778B1/en not_active Expired - Lifetime
-
2000
- 2000-01-05 AU AU10106/00A patent/AU760615B2/en not_active Expired
-
2001
- 2001-09-06 US US09/949,404 patent/US6599508B1/en not_active Expired - Lifetime
-
2003
- 2003-07-01 US US10/610,928 patent/US20040202679A1/en not_active Abandoned
-
2005
- 2005-04-27 JP JP2005130613A patent/JP2005270111A/ja not_active Withdrawn
-
2006
- 2006-02-21 US US11/358,474 patent/US7416732B2/en not_active Expired - Fee Related
-
2007
- 2007-12-14 LU LU91401C patent/LU91401I2/fr unknown
- 2007-12-14 NL NL300323C patent/NL300323I2/nl unknown
- 2007-12-14 LU LU91390C patent/LU91390I2/fr unknown
- 2007-12-14 NL NL300324C patent/NL300324I1/nl unknown
-
2008
- 2008-08-25 US US12/197,591 patent/US20110015376A1/en not_active Abandoned
- 2008-11-27 JP JP2008303257A patent/JP2009102327A/ja not_active Withdrawn
-
2011
- 2011-10-04 JP JP2011220539A patent/JP2012010713A/ja not_active Withdrawn
-
2013
- 2013-05-29 JP JP2013112548A patent/JP2013213034A/ja not_active Withdrawn
-
2014
- 2014-11-21 JP JP2014236222A patent/JP5794747B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6361778B1 (en) | Carboxyl terminal of papillomavirus L1 region is not required for formation of virus-like particles | |
| EP0592480B1 (en) | Use of papillomavirus L2 protein for therapeutic treatment of papillomavirus tumours or lesions | |
| ES2572628T3 (es) | Método in vitro para desmontaje/remontaje de partículas análogas al virus del papiloma humano (VLP) | |
| ES2317910T3 (es) | Formas (fijas) estables e proteinas de capside l1 virales, proteinas de fusion y sus utilizaciones. | |
| WO1993020844A1 (en) | Papillomavirus e7 protein | |
| WO2008145021A1 (fr) | Protéine l1 tronquée du papillomavirus humain de type 6 | |
| KR101515445B1 (ko) | 세포 투과 펩타이드 및 치료 작용을 갖는 생체 분자에 결합된 이의 용도 | |
| EP2172488A1 (en) | Material with immunogenicity | |
| ES2323634T3 (es) | Proteinas quimericas l1 del virus del paliloma humano 16 que contienen un peptido l2, particulas tipo virus preparadas a partir de estas proteinas y un metodo para preparar las particulas. | |
| ES2273376T3 (es) | Formulaciones de vacunas recombinantes frente a papilomas. | |
| CN102336822A (zh) | 截短的人乳头瘤病毒58型l1蛋白 | |
| KR20200035963A (ko) | 인간 유두종 바이러스 타입 16의 l1 단백질의 변이체 | |
| WO2025093041A1 (zh) | 非洲猪瘟病毒CD2v蛋白的免疫原性组合物及其应用 | |
| CN110028559A (zh) | 一种铜绿假单胞菌疫苗重组蛋白及其编码基因和它们的应用 | |
| RU2377305C1 (ru) | Мукозальная вакцина для иммунотерапии заболеваний, обусловленных вирусами папилломы человека, и способ лечения с ее использованием (варианты) | |
| AU2003235191B2 (en) | Papilloma virus-like particles, fusion proteins as well as processes for their production | |
| AU2006252125B2 (en) | Papiloma virus-like particles, fusion proteins as well as processes for their production | |
| RU2280691C2 (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДА pCI-neo-ODC-nsP1 И ЕЕ ВАРИАНТЫ pCI-neo-ODC-E2-L И pCI-neo-ODC-E2-M, КОДИРУЮЩИЕ БЕЛКИ ВИРУСА ВЕНЕСУЭЛЬСКОГО ЭНЦЕФАЛОМИЕЛИТА ЛОШАДЕЙ И БЕЛОК ОРНИТИНДЕКАРБОКСИЛАЗЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ РАЗРАБОТКИ СРЕДСТВ ПРОФИЛАКТИКИ ВИРУСНЫХ ИНФЕКЦИОННЫХ ЗАБОЛЕВАНИЙ (НА ПРИМЕРЕ ВИРУСА ВЭЛ) | |
| AU719837B2 (en) | Pharmaceuticals based on papillomaviruses | |
| CN101846679A (zh) | 筛选含有外源融合基因HIV/env/IFNα-2b的重组痘苗病毒的方法 | |
| HK1098766A (en) | Papilloma virus-like particles, fusion proteins and process for producing the same | |
| KR20070078562A (ko) | 대장균의 열에 불안정한 내독소의 ｂ 서브유닛과 사람파필로마바이러스 16형 ｅ7의 융합단백질 및 이의 용도 | |
| KR20070078559A (ko) | 대장균의 열 불안정성 내독소 ｂ 서브유닛과 사람파필로마바이러스 16형 ｅ6의 단백질이 융합된 단백질 및이의 용도 | |
| HK1205147B (en) | Truncated l1 proteins of human papillomavirus type 45 | |
| HK1001309B (en) | Use of papillomavirus l2 protein for therapeutic treatment of papillomavirus tumours or lesions |